On Friday, NovoCure Ltd (NASDAQ: NVCR) was -4.66% drop from the session before settling in for the closing price of $18.46. A 52-week range for NVCR has been $14.17 – $34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -83.87%. When this article was written, the company’s average yearly earnings per share was at -4.34%. With a float of $98.78 million, this company’s outstanding shares have now reached $111.48 million.
Let’s determine the extent of company efficiency that accounts for 1488 employees. In terms of profitability, gross margin is 77.16%, operating margin of -26.84%, and the pretax margin is -20.88%.
NovoCure Ltd (NVCR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NovoCure Ltd stocks. The insider ownership of NovoCure Ltd is 11.39%, while institutional ownership is 77.16%. The most recent insider transaction that took place on Jun 03 ’25, was worth 17,259. In this transaction Director of this company sold 999 shares at a rate of $17.28, taking the stock ownership to the 3,054 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Director sold 999 for $17.31, making the entire transaction worth $17,297. This insider now owns 81,229 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -4.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.68% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
You can see what NovoCure Ltd (NVCR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Looking closely at NovoCure Ltd (NASDAQ: NVCR), its last 5-days average volume was 0.99 million, which is a drop from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic %D was 67.37%.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 36.00%, which indicates a significant decrease from 56.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.74 in the past 14 days, which was lower than the 0.93 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.68, while its 200-day Moving Average is $20.18. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $18.05. Second resistance stands at $18.49. The third major resistance level sits at $18.74. If the price goes on to break the first support level at $17.36, it is likely to go to the next support level at $17.11. Should the price break the second support level, the third support level stands at $16.67.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
There are 111,486K outstanding shares of the company, which has a market capitalization of 1.96 billion. As of now, sales total 605,220 K while income totals -168,630 K. Its latest quarter income was 154,990 K while its last quarter net income were -34,320 K.
